What is the latest price of Ensifentrine?

Ohtuvayre (Ensifentrine)-Ensifentine Inhalation Suspension is a new inhaled drug mainly used to treat chronic obstructive pulmonary disease (COPD). It is a dual-action drug that not only has anti-inflammatory effects, but also dilates the airways and improves the patient's respiratory function. Exefentine works by inhibiting two key enzymes - lipase and adenyl diphosphate acylase - to reduce airway inflammation while relaxing airway smooth muscle, thereby reducing dyspnea and other symptoms.

At present, Ensefentin is not yet on the market in China, so it is not covered by medical insurance. Patients need to pay for it at their own expense when using this drug. In overseas markets, especially in the United States, the drug has been approved and launched. The common specification is 3mg/2.5mL (60 doses), and the price is about more than 40,000 yuan. The specific price will vary due to exchange rate fluctuations. This can be a considerable financial burden for many patients.

Although clinical trials of exefantine have shown promising efficacy, its high price prohibits many patients. Especially in China, there are many types of drugs for the treatment of COPD, but the prices of many new drugs are at a high level, so many patients often face financial pressure when choosing drugs. In addition, because exefantine has not yet been included in medical insurance, patients need to bear the entire cost of the drug when receiving treatment, which also poses challenges to many families.

In the future, as domestic drug approval policies are gradually relaxed and competition in the drug market intensifies, Exefantine may be launched in the Chinese market. If the drug can be successfully launched and included in medical insurance, it will provide more COPD patients with more convenient treatment options and reduce their financial burden.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html